Suchergebnisse - "Meroni, Pier Luigi"

PubPharm (14)

1

Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus : post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou et al

enthalten in: Annals of the rheumatic diseases | 2022

von Bettiol, A. | Pregnolato, F. | Sciascia, S. | +3

CommentOn: Ann Rheum Dis. 2020 Feb;79(2):304-307. - PMID 31712248

2

2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19

enthalten in: Annals of the rheumatic diseases | 2022

von Alunno, A. | Najm, A. | Machado, P. | +21

3

Successful sequential therapy with rituximab and belimumab in patients with active systemic lupus erythematosus : a case series

enthalten in: Clinical and experimental rheumatology | 2018

von Gualtierotti, R. | Borghi, M. | Gerosa, M. | +4

4

Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study

enthalten in: Journal of autoimmunity | 2018

von Iaccarino, L. | Andreoli, L. | Bocci, E. | +25

5

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors : results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

enthalten in: Lancet (London, England) | 2017

von Nash, P. | Kirkham, B. | Okada, M. | +84

CommentIn: Lancet. 2017 Jun 10;389(10086):2268-2270. - PMID 28551071

6

Prothrombotic biomarkers in patients with rheumatoid arthritis : the beneficial effect of IL-6 receptor blockade

enthalten in: Clinical and experimental rheumatology | 2016

von Gualtierotti, R. | Ingegnoli, F. | Griffini, S. | +3

7

Recognition and management of antiphospholipid syndrome

enthalten in: Current opinion in rheumatology | 2016

von Gerosa, M. | Meroni, P. | Erkan, D.

8

New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors : A systematic analysis

enthalten in: Autoimmunity reviews | 2015

von Meroni, P. | Valentini, G. | Ayala, F. | +2

9

Newly identified antiatherosclerotic activity of methotrexate and adalimumab : complementary effects on lipoprotein function and macrophage cholesterol metabolism

enthalten in: Arthritis & rheumatology (Hoboken, N.J.) | 2015

von Ronda, N. | Greco, D. | Adorni, M. | +10

10

Survival on treatment with second-line biologic therapy : a cohort study comparing cycling and swap strategies

enthalten in: Rheumatology (Oxford, England) | 2014

von Favalli, E. | Biggioggero, M. | Marchesoni, A. | +1

ErratumIn: Rheumatology (Oxford). 2015 Jul;54(7):1337. - PMID 26047991